Medical and Scientific Advisory Board

Internationally recognised for his work in virus infection, Prof. Young was appointed as a Pro-Vice Chancellor at the University of Warwick in January 2013 with responsibility for strategic planning and resources. In 2016 he became Vice-President at the University of Warwick, encompassing his existing responsibilities, while highlighting his leadership in the University’s engagement activities in China and Hong Kong. In 2018 Professor Young was appointed as Pro-Dean for External Affairs at Warwick Medical School and Director of the Warwick Cancer Research Centre. In 2019 Professor Young became co-lead of the new Warwick Health Global Research Priority.

Before joining the University of Warwick, he was Pro-Vice Chancellor and Head of the College of Medical and Dental Sciences at the University of Birmingham where he maintains an honorary Professorship in addition to other Professorships at Monash (Australia), Yat-sen (China) and Gadjah Mada (Indonesia) universities.

Professor Young is listed amongst the World’s most cited scientists in the ISI’s (Institute for Scientific Information) list of Highly Cited Researchers.

Professor Mike Holmes BSc MB ChB MSc DRCOG FRCGP is recognised for his work for delivering at-scale primary care across Yorkshire and the Humber. Professor Mike Holmes is Vice Chair of the Royal College of General Practitioners with responsibility for Membership and International work. He has been a partner at Haxby Group since 2002, a large multi-site practice caring for over 60,000 patients across York and Hull.  Professor Holmes has interests in clinical leadership, addressing health inequalities and the development of a multi-professional workforce in primary care. He chairs the regional faculty of Advanced Clinical Practitioners and Physician Associates and he is an Honorary Professor in the Department of Health Sciences at the University of York.

Tara Moore, Professor of Personalised Medicine, holds a chair at Ulster University in Northern Ireland where her research team concentrate on partner diagnostics and therapeutics for genetic disease. Her work is disseminated worldwide through her contribution to guest lectures and workshops and internationally co-authored peer reviewed publications. Tara has contributed to numerous textbooks and authored over 150 publications in high impact peer reviewed journals reflecting internationally competitive research of high quality with 3790 total citations, h-index of 33 and i10-index of 72.

Tara concurrently holds position of Chief of Research and Innovation for USA based international company Avellino Labs in Menlo Park, San Francisco USA. Avellino is a leading diagnostic company with its provision for COVID-19 consistently gaining number 1 position for turn-around time and top 10 in the total test count dashboard for California.

Tara is a Fellow of Royal Society of Biology, Royal Society of Arts, Royal Society of Medicine and Honorary Fellow of Royal College of Physicians (London) FRCP, FFLM. The culmination of Tara’s contribution to health and improving people’s lives whilst inspiring others to see the opportunities to make a difference through science was recognised with the prestigious WISE award. Tara was nominated and voted as a double awardee for the Ophthalmologist’s Power List 2019 in two categories- Emerging Leaders: Movers and shakers influencing the world of ophthalmology – and beyond alongside her nomination in Inventors: Intelligent and inquisitive minds opening the door to the future of ophthalmology. Tara was also awarded THE Research Supervisor of the year award 2020 and a Royal Irish Academy- US Chambers of Commerce Research Innovation Award 2020. Most recently, Tara’s research underpinned multi-million-dollar series B funding to accelerate therapeutic programmes to treat rare genetic conditions. Tara represents Northern Ireland on the UKRI Strengths in Places panel for the distribution of research and innovation funding to support significant regional growth.

Dene has 30+ years of experience in the development, manufacture and commercialisation of immunodiagnostic assays and systems, particularly on-site and point of care systems. Previously Technical Director at Abingdon Health and was Group Technical Director at Alere Toxicology (now Abbot) and held similar positions at Concateno plc and Cozart plc. Dene was instrumental in the development of the successful Cozart® RapiScan, Alere DDS2®, and variants of this saliva-based on-site multiplexed rapid drug testing system.